BioSpace News Archive

IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance.

Exicure, Inc. today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board of directors (the “Board”).

Seres Therapeutics, Inc. today announced that it has entered into a new $250 million senior secured debt facility (“Term Loan Facility”) provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).

Alphyn Biologics will present for the first time new pediatric data from its Phase 2a clinical trial of a topical candidate for mild-to-moderate atopic dermatitis (AD) at the 22nd European Society for Pediatric Dermatology Congress.

Dante Genomics today announced it has been awarded a highly coveted Innovation Grant from the Italian Government to measure the impact of whole genome sequencing and pharmacogenomics for patients with High Grade Serous Ovarian Cancer (HSOC).

Palatin Technologies, Inc. today announced the presentation of a poster entitled Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.

Outlook Therapeutics, Inc. announced that Russ Trenary, President and Chief Executive Officer and Glen Olsheim as Executive Director, Commercial Excellence of Outlook Therapeutics will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at Nasdaq on Tuesday, May 2, 2023 at 2:00 PM ET.

Humacyte, Inc. (Nasdaq: HUMA) today announced a new collaboration to advance the development of Humacyte’s Biovascular Pancreas (BVP) product candidate.